Study of JDB0131 for drug-resistant TB
Treatments studied
Part of Infections clinical trials.
This trial tests a new tablet called JDB0131 for people with tuberculosis (TB) that is resistant to the antibiotic rifampicin. The goal is to see if it can effectively treat this hard-to-treat form of TB.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 14 and 65 years old.
- You weigh between 40 and 90 kilograms.
- You have active TB that is resistant to the antibiotic rifampicin (confirmed by lab tests within the last 3 months).
- Your sputum test shows TB bacteria (moderate or higher on two tests, or high on one and moderate on another).
- If you are currently on TB treatment, you are willing to stop and have a 7-day break before starting the study drug.
- You agree to use effective birth control during the study and for 6 months after stopping the drug (if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new “triple-dose” set of medicines to treat people whose tuberculosis (TB) has come back in the lungs. If you qualify, the goal is to improve cure rates and reduce the chance of TB returning again.
This study tests different treatment plans for people with tuberculosis (TB) that can be cured with standard medicines. It aims to find the best treatment for each person based on their risk score, which may lead to shorter or more effective treatment.
This trial tests a new, all-oral, shorter treatment regimen for tuberculosis that is resistant to rifampicin, a key antibiotic. It may offer a more convenient and effective option for patients with this difficult-to-treat infection.
This study tests new combinations of drugs for treating pulmonary tuberculosis (TB). The goal is to find more effective and safer treatments than the current standard.
This trial tests a combination of drugs for people with active tuberculosis who have not been treated before. It aims to find a better way to treat TB, even if the bacteria are resistant to some drugs.
This Phase 2 study tests treatment for people with newly diagnosed, drug-susceptible pulmonary (lung) tuberculosis (TB). It aims to see whether the study treatment works well and is safe for curing TB.
Hear when a new Tuberculosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.